Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 2
2022 10
2023 3
2024 2
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean belimumabs bliss ln lupus nephritis (3 results)?
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA. Furie R, et al. N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180. N Engl J Med. 2020. PMID: 32937045 Clinical Trial.
BACKGROUND: In adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared with placebo, when added to standard therapy (mycophenolate mofetil or cyclophosphamide-azathioprine), are unknown. ...The safety profile of bel …
BACKGROUND: In adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared with pl …
Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
Furie R, Rovin BH, Houssiau F, Contreras G, Teng YKO, Curtis P, Green Y, Okily M, Madan A, Roth DA. Furie R, et al. Clin J Am Soc Nephrol. 2022 Nov;17(11):1620-1630. doi: 10.2215/CJN.02520322. Epub 2022 Oct 27. Clin J Am Soc Nephrol. 2022. PMID: 36302567 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVES: In the BLISS-LN study, belimumab improved kidney outcomes in adult patients with active lupus nephritis. This 28-week open-label extension of BLISS-LN assessed belimumab's safety and efficacy. DESI …
BACKGROUND AND OBJECTIVES: In the BLISS-LN study, belimumab improved kidney outcomes in adult patients with active l …
Systemic lupus erythematosus.
Hoi A, Igel T, Mok CC, Arnaud L. Hoi A, et al. Lancet. 2024 May 25;403(10441):2326-2338. doi: 10.1016/S0140-6736(24)00398-2. Epub 2024 Apr 17. Lancet. 2024. PMID: 38642569 Review.
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterised by the presence of autoantibodies towards nuclear antigens, immune complex deposition, and chronic inflammation at classic target organs such as skin, joints, and kidneys. ...In the last …
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease characterised by the presence of autoantibodies towards nucl …
Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.
Anders HJ, Furie R, Malvar A, Zhao MH, Hiromura K, Weinmann-Menke J, Green Y, Jones-Leone A, Negrini D, Levy RA, Lightstone L, Tanaka Y, Rovin BH. Anders HJ, et al. Nephrol Dial Transplant. 2023 Nov 30;38(12):2733-2742. doi: 10.1093/ndt/gfad167. Nephrol Dial Transplant. 2023. PMID: 37463054 Free PMC article. Clinical Trial.
BACKGROUND: Data on belimumab efficacy in patients with lupus nephritis (LN) according to diagnosis duration or induction therapy are limited. ...METHODS: BLISS-LN randomized 448 patients with active LN to monthly intravenous belimumab 10 …
BACKGROUND: Data on belimumab efficacy in patients with lupus nephritis (LN) according to diagnosis duration or inducti …
A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
Rovin BH, Furie R, Teng YKO, Contreras G, Malvar A, Yu X, Ji B, Green Y, Gonzalez-Rivera T, Bass D, Gilbride J, Tang CH, Roth DA. Rovin BH, et al. Kidney Int. 2022 Feb;101(2):403-413. doi: 10.1016/j.kint.2021.08.027. Epub 2021 Sep 22. Kidney Int. 2022. PMID: 34560137 Free article. Clinical Trial.
We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN), a Phase 3, multinational, double-blind, 104-week trial, in which 448 patients with lupus nephritis were randomized to receive intr …
We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN), a Ph …
Repeat kidney biopsy findings of lupus nephritis patients in clinical remission treated with Mycophenolate associated with Belimumab or Mycophenolate plus standard of care therapy. A "post-hoc" analysis of participants in the BLISS-LN and open label extension study belonging to a single center.
Malvar A, Alberton V, Recalde C, Heguilen R. Malvar A, et al. Lupus. 2023 Oct;32(12):1394-1401. doi: 10.1177/09612033231204070. Epub 2023 Sep 27. Lupus. 2023. PMID: 37754750 Clinical Trial.
BACKGROUND: Lupus nephritis affects 40 to 70% of Systemic Lupus Erythematous(SLE) patients increasing their morbi-mortality; therefore, successful treatments are required to improve outcomes. ...RESULTS: All the patients in the Belimumab group showed a …
BACKGROUND: Lupus nephritis affects 40 to 70% of Systemic Lupus Erythematous(SLE) patients increasing their morbi-morta …
Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.
Plüß M, Piantoni S, Tampe B, Kim AHJ, Korsten P. Plüß M, et al. Hum Vaccin Immunother. 2022 Nov 30;18(5):2072143. doi: 10.1080/21645515.2022.2072143. Epub 2022 May 19. Hum Vaccin Immunother. 2022. PMID: 35588699 Free PMC article. Review.
In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus nephritis (LN) still represents a major life-threatening complication of the …
In recent years, advances in the treatment and management of patients with systemic lupus erythematosus (SLE) have improved their lif …
Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
Yu X, Chen N, Xue J, Mok CC, Bae SC, Peng X, Chen W, Ren H, Li X, Noppakun K, Gilbride JA, Green Y, Ji B, Liu C, Madan A, Okily M, Tang CH, Roth DA. Yu X, et al. Am J Kidney Dis. 2023 Mar;81(3):294-306.e1. doi: 10.1053/j.ajkd.2022.06.013. Epub 2022 Sep 2. Am J Kidney Dis. 2023. PMID: 36058429 Free article. Clinical Trial.
RATIONALE & OBJECTIVE: Belimumab improved kidney outcomes in patients with active lupus nephritis (LN) in BLISS-LN, leading to its approval in the United States and the European Union. As data on treatment of East Asian patients with LN are …
RATIONALE & OBJECTIVE: Belimumab improved kidney outcomes in patients with active lupus nephritis (LN) in BLISS …
A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis.
Furie R, Anders HJ, Bertsias G, Delgado A, Levy RA, Curtis P, O'Shea C, Tomlinson R, Rovin B. Furie R, et al. Kidney Int. 2026 May 21:S0085-2538(26)00397-2. doi: 10.1016/j.kint.2026.03.030. Online ahead of print. Kidney Int. 2026. PMID: 42173278 Free article.
INTRODUCTION: Belimumab, approved for systemic lupus erythematosus (SLE) and lupus nephritis (LN) treatment, is a B-cell-modulating monoclonal antibody that selectively inhibits B-lymphocyte stimulator (BLyS) and downregulates autoreactive B-cells. ... …
INTRODUCTION: Belimumab, approved for systemic lupus erythematosus (SLE) and lupus nephritis (LN) treatment, is …
A review of the AURORA and BLISS trials: will it revolutionize the treatment of lupus nephritis?
Asif S, Bargman J, Auguste B. Asif S, et al. Curr Opin Nephrol Hypertens. 2022 May 1;31(3):278-282. doi: 10.1097/MNH.0000000000000792. Epub 2022 Mar 4. Curr Opin Nephrol Hypertens. 2022. PMID: 35249969 Review.
RECENT FINDINGS: The recent findings from AURORA 1 and BLISS LN trials led the FDA to approve voclosporin and belimumab for the treatment of lupus nephritis. ...SUMMARY: Both voclosporin and belimumab are costly and have not shown any ear …
RECENT FINDINGS: The recent findings from AURORA 1 and BLISS LN trials led the FDA to approve voclosporin and belimumab …
19 results